Real-life Evaluation of the Daivobet® Gel Applicator
Launched by LEO PHARMA · Aug 2, 2016
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Dermatologist or general practitioner has decided to initiate treatment with Daivobet® gel Applicator
- Exclusion Criteria:
- • Indication not within the approved labelling in France
- • Contraindication for treatment with calcipotriol or betamethasone dipropionate
- • Informed consent to participate in the study has not been obtained
About Leo Pharma
LEO Pharma is a global pharmaceutical company dedicated to developing innovative therapies for dermatological and critical care conditions. With a strong focus on research and development, LEO Pharma aims to improve the lives of patients through advanced treatments and a commitment to high-quality standards. The company collaborates with healthcare professionals and stakeholders to address unmet medical needs and drive scientific progress in the field. Through its clinical trials, LEO Pharma seeks to enhance therapeutic options and provide effective solutions for patients suffering from skin diseases and other related health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Charenton Le Pont, , France
Patients applied
Trial Officials
Mathilde Kemula, MD
Principal Investigator
Cabinet de Dermatologie, Dr. Mathilde Kemula
Frederic Bonnier, MD
Principal Investigator
General Practice, 356 Rue de Charles de Gaulle, 91400 Orsay
Nathalie Quiles, MD
Principal Investigator
Hôpital Saint Joseph, 26 Boulevard de Louvain, Marseille
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials